Previous 10 | Next 10 |
Cabaletta Bio (NASDAQ: CABA ): Q1 GAAP EPS of -$0.33 misses by $0.10 . More news on: Cabaletta Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the ...
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Des...
Summary Cabaletta Bio ( CABA ) is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases. The company was founded in 2017 to use clinically-validated CAR-T technologies to target B-cell mediated autoimmune disease . A primary feature of autoimmune di...
One biotech IPO is scheduled for the week ahead, and pipeline activity indicates that a few more may be on the way. ORIC Pharmaceuticals (ORIC), a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, plans to raise $75 million at a $424 million market cap. The...
There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our 1Q20 IPO Review, the first IPOs to emerge from the shutdown...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Cabaletta Bio (NASDAQ: CABA ): Q4 GAAP EPS of -$0.33 beats by $0.14 . More news on: Cabaletta Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay in reporting the acute safety data from the first cohort of the DesCAARTes TM trial due to the COVID-19 pande...
PHILADELPHIA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...